Does the media refer more to INBX or RYTM?

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Rhythm Pharmaceuticals' score of 1.34 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, INBX or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibrx Biosciences N/A N/A -$140.05M -$8.88 N/A Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is INBX or SRRK more profitable?

Scholar Rock's return on equity of -160.19% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Scholar Rock N/A -160.19% -87.18%

Does the media refer more to INBX or SRRK?

In the previous week, Scholar Rock had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Scholar Rock and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Scholar Rock's score of 1.40 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGON or INBX?

In the previous week, CG Oncology had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 9 mentions for CG Oncology and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat CG Oncology's score of 1.43 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or INBX?

In the previous week, Mirum Pharmaceuticals had 12 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 17 mentions for Mirum Pharmaceuticals and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Mirum Pharmaceuticals' score of 1.07 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ERAS or INBX?

Erasca is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Inhibrx Biosciences N/A N/A -$140.05M -$8.88 N/A

Is ERAS or INBX more profitable?

Erasca's return on equity of -38.43% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media favor ERAS or INBX?

In the previous week, Erasca had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 10 mentions for Erasca and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Erasca's score of 1.23 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibrx Biosciences (INBX) Competitors

$121.17 -1.09 (-0.89%)

As of 09/4/2026 04:00 PM Eastern

Compare

INBX vs. RYTM, SRRK, CGON, MIRM, and ERAS

Should you buy Inhibrx Biosciences stock or one of its competitors? Inhibrx Biosciences's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inhibrx Biosciences compare to Rhythm Pharmaceuticals?

Inhibrx Biosciences (NASDAQ:INBX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Inhibrx Biosciences has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Rhythm Pharmaceuticals' return on equity of -159.87% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

In the previous week, Rhythm Pharmaceuticals had 6 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Rhythm Pharmaceuticals' score of 1.34 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Inhibrx Biosciences has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A
Rhythm Pharmaceuticals	$239.92M	29.35	-$196.54M	-$3.11	N/A

Inhibrx Biosciences presently has a consensus price target of $197.50, indicating a potential upside of 62.99%. Rhythm Pharmaceuticals has a consensus price target of $141.12, indicating a potential upside of 37.35%. Given Inhibrx Biosciences' higher probable upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market.

Summary

Inhibrx Biosciences beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Scholar Rock?

Inhibrx Biosciences (NASDAQ:INBX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Inhibrx Biosciences currently has a consensus target price of $197.50, suggesting a potential upside of 62.99%. Scholar Rock has a consensus target price of $58.77, suggesting a potential upside of 6.22%. Given Inhibrx Biosciences' higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Inhibrx Biosciences has a beta of 3.66, indicating that its stock price is 266% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Scholar Rock's return on equity of -160.19% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Scholar Rock	N/A	-160.19%	-87.18%

In the previous week, Scholar Rock had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Scholar Rock and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Scholar Rock's score of 1.40 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Inhibrx Biosciences and Scholar Rock tied by winning 7 of the 14 factors compared between the two stocks.

How does Inhibrx Biosciences compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Inhibrx Biosciences has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23M	1,062.74	-$160.99M	-$2.69	N/A
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A

CG Oncology presently has a consensus target price of $83.18, indicating a potential upside of 11.40%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 62.99%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CG Oncology has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, meaning that its stock price is 266% more volatile than the broader market.

In the previous week, CG Oncology had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 9 mentions for CG Oncology and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat CG Oncology's score of 1.43 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Summary

Inhibrx Biosciences beats CG Oncology on 9 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus target price of $137.31, indicating a potential upside of 36.09%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 62.99%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Mirum Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.60	-$23.36M	-$14.55	N/A
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A

Mirum Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, indicating that its share price is 266% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 12 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 17 mentions for Mirum Pharmaceuticals and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Mirum Pharmaceuticals' score of 1.07 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Summary

Mirum Pharmaceuticals beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Erasca?

Erasca (NASDAQ:ERAS) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Erasca's return on equity of -38.43% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

67.8% of Erasca shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Erasca is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A

Erasca has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, indicating that its stock price is 266% more volatile than the broader market.

Erasca currently has a consensus price target of $22.09, indicating a potential upside of 36.45%. Inhibrx Biosciences has a consensus price target of $197.50, indicating a potential upside of 62.99%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Erasca had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 10 mentions for Erasca and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.46 beat Erasca's score of 1.23 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Erasca and Inhibrx Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.78B	$4.02B	$7.26B	$12.90B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-13.65	12.71	273.83	25.45
Price / Sales	N/A	1,310.70	608.03	79.09
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	-33.66	16.15	12.85	6.17
Net Income	-$140.05M	-$22.80M	$3.49B	$350.08M
7 Day Performance	-1.82%	0.31%	1.04%	-0.14%
1 Month Performance	44.44%	8.25%	5.52%	1.02%
1 Year Performance	329.99%	49.17%	24.39%	14.51%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	2.8729 of 5 stars	$121.17 -0.9%	$197.50 +63.0%	+337.1%	$1.78B	N/A	N/A	166	Positive News
RYTM Rhythm Pharmaceuticals	2.8926 of 5 stars	$104.74 -1.3%	$141.12 +34.7%	-1.8%	$7.27B	$189.76M	N/A	140	Positive News Insider Trade
SRRK Scholar Rock	1.8392 of 5 stars	$55.89 -1.6%	$58.77 +5.2%	+70.6%	$6.92B	N/A	N/A	140	Positive News
CGON CG Oncology	3.2457 of 5 stars	$75.86 +0.9%	$83.18 +9.7%	+141.3%	$6.66B	$4.04M	N/A	61	Positive News
MIRM Mirum Pharmaceuticals	3.6716 of 5 stars	$98.34 +0.3%	$137.31 +39.6%	+36.0%	$6.37B	$521.31M	N/A	140	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. RYTM, SRRK, CGON, MIRM, and ERAS

How does Inhibrx Biosciences compare to Rhythm Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Summary

How does Inhibrx Biosciences compare to CG Oncology?

Summary

How does Inhibrx Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. RYTM, SRRK, CGON, MIRM, and ERAS

How does Inhibrx Biosciences compare to Rhythm Pharmaceuticals?

Is INBX or RYTM more profitable?

Does the media refer more to INBX or RYTM?

Do insiders and institutionals believe in INBX or RYTM?

Which has better valuation & earnings, INBX or RYTM?

Do analysts recommend INBX or RYTM?

Which has more volatility & risk, INBX or RYTM?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Do analysts prefer INBX or SRRK?

Which has more risk & volatility, INBX or SRRK?

Is INBX or SRRK more profitable?

Does the media refer more to INBX or SRRK?

Which has stronger earnings & valuation, INBX or SRRK?

Do institutionals and insiders have more ownership in INBX or SRRK?

Summary

How does Inhibrx Biosciences compare to CG Oncology?

Which has stronger valuation and earnings, CGON or INBX?

Do analysts prefer CGON or INBX?

Do insiders & institutionals hold more shares of CGON or INBX?

Which has more risk and volatility, CGON or INBX?

Does the media favor CGON or INBX?

Is CGON or INBX more profitable?

Summary

How does Inhibrx Biosciences compare to Mirum Pharmaceuticals?

Do insiders and institutionals believe in MIRM or INBX?

Do analysts recommend MIRM or INBX?

Which has better earnings & valuation, MIRM or INBX?

Which has more risk and volatility, MIRM or INBX?

Does the media prefer MIRM or INBX?

Is MIRM or INBX more profitable?

Summary

How does Inhibrx Biosciences compare to Erasca?

Is ERAS or INBX more profitable?

Do insiders & institutionals believe in ERAS or INBX?

Which has higher valuation & earnings, ERAS or INBX?

Which has more risk & volatility, ERAS or INBX?

Do analysts recommend ERAS or INBX?

Does the media favor ERAS or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools